Decitabine for poor graft function after stem cell transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether a drug called decitabine can help improve poor graft function after a donor stem cell transplant. Poor graft function means your blood counts stay low because the donor stem cells are not working well enough. Decitabine may help stimulate the bone marrow to produce more blood cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a donor stem cell transplant and, at least 28 days after it, your blood counts are still low (white blood cells, platelets, or hemoglobin) for more than two weeks straight.
- The donor cells have fully taken over your bone marrow, and your original disease is in remission.
- You do not have severe graft-versus-host disease (GVHD) that is uncontrolled, and you have no active infections or severe organ problems.
- Your cancer has not come back (no relapse), and you have not had graft failure.
- You are not allergic to decitabine and have not received it or been in another trial within the last month.
- Your overall health is fairly good (ECOG score 0-2) and you are expected to live at least another month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a medicine called decitabine along with an umbilical cord blood infusion can help improve blood counts in people whose counts are not recovering well after a stem cell transplant. It aims to boost your body's ability to make healthy blood cells.
This study tests whether giving extra stem cells from your original donor can help your blood cell counts recover after a transplant. It is for people whose new immune system has not fully engrafted or whose counts are dangerously low.
This study tests whether umbilical cord blood cells can help patients whose blood counts have dropped again after a stem cell transplant. It may be an option for people who have recovered initially but later develop low blood cell levels.
This trial tests adding two new drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant for people with certain types of leukemia or myelodysplastic syndrome. The goal is to see if this combination can improve outcomes.
This trial studies whether adding decitabine plus chemotherapy before a stem cell transplant can better control “minimal residual disease” (very small amounts of leukemia left behind) in certain high-risk acute leukemia types. It may help reduce the chance of the leukemia coming back after transplant.
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
Hear when a new Poor Graft Function trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.